RBC Capital Maintains Outperform on Alnylam Pharmaceuticals, Lowers Price Target to $230
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has maintained an 'Outperform' rating on Alnylam Pharmaceuticals (NASDAQ:ALNY), but lowered the price target from $235 to $230.
November 03, 2023 | 6:06 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Alnylam Pharmaceuticals' price target has been lowered by RBC Capital from $235 to $230, though the 'Outperform' rating is maintained.
The news is directly about Alnylam Pharmaceuticals and its price target being lowered by RBC Capital. This could potentially impact investor sentiment, though the 'Outperform' rating being maintained suggests that the overall outlook remains positive. The impact on the stock price in the short term is uncertain, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100